全面分析 TDG 在肝细胞癌中的预后价值和生物学功能。
Comprehensive analysis of the prognostic value and biological function of TDG in hepatocellular carcinoma.
机构信息
Department of Hepatobiliary Surgery, Department of Organ Transplantation, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Department of Surgery, Zunyi Medical University, Zunyi, Guizhou, China.
出版信息
Cell Cycle. 2023 Jun;22(12):1478-1495. doi: 10.1080/15384101.2023.2216501. Epub 2023 May 24.
Epigenetics plays an important role in the malignant progression of tumors, in which DNA methylation can alter genetic performance without altering the DNA sequence. As a key regulator demethylation, thymine-DNA glycosylase (TDG) has been reported to participate in malignant progression of multiple tumors. In this study, we demonstrate that TDG is highly expressed in hepatocellular carcinoma (HCC) and its high expression is closely related to the poor prognosis of patients. Decreasing TDG expression can significantly inhibit the malignant biological behavior of HCC cells. ABL proto-oncogene 1(ABL1) was identified as a downstream gene regulated by TDG demethylation. In addition, TDG can affect the Hippo signaling pathway through ABL1 to regulate HCC cell proliferation, apoptosis, invasion and migration. Overall, our study demonstrated that TDG reduces DNA methylation of ABL1, increases ABL1 protein expression, and affects the Hippo signaling pathway to regulate the malignant progression of HCC.
表观遗传学在肿瘤的恶性进展中起着重要作用,其中 DNA 甲基化可以改变遗传表现而不改变 DNA 序列。作为关键的去甲基化调节因子,胸腺嘧啶-DNA 糖基化酶 (TDG) 已被报道参与多种肿瘤的恶性进展。在本研究中,我们证明 TDG 在肝细胞癌 (HCC) 中高表达,其高表达与患者的不良预后密切相关。降低 TDG 表达可显著抑制 HCC 细胞的恶性生物学行为。ABL 原癌基因 1 (ABL1) 被鉴定为 TDG 去甲基化调控的下游基因。此外,TDG 可以通过 ABL1 影响 Hippo 信号通路来调节 HCC 细胞的增殖、凋亡、侵袭和迁移。总的来说,我们的研究表明 TDG 通过降低 ABL1 的 DNA 甲基化,增加 ABL1 蛋白表达,并影响 Hippo 信号通路来调节 HCC 的恶性进展。
相似文献
Biochem Biophys Res Commun. 2013-6-29
Biochem Biophys Res Commun. 2014-4-12
Oncogene. 2019-1-23
Genomics Proteomics Bioinformatics. 2014-1-3
引用本文的文献
Asian Pac J Cancer Prev. 2023-11-1
本文引用的文献
Cancers (Basel). 2022-2-1
Acta Biochim Biophys Sin (Shanghai). 2021-10-12
Nat Rev Drug Discov. 2020-6-17
Anticancer Res. 2020-5